C5 and paroxysmal nocturnal hemoglobinuria: Based on these results, pegcetacoplan was approved by the FDA for patients with PNH who are either treatment‐naive or switching from anti‐C5 monoclonal antibodies, and by EMA just for PNH patients who remain anemic after a minimum of 3 months of treatment with anti‐C5 agents.